ZAP-70 in B-cell chronic lymphocytic leukemia: clinical significance and methods of detection
Authors:
L. Smolej 1; L. Saudková 2; M. Špaček 2; T. Kozák 2
Authors place of work:
Oddělení klinické hematologie II. interní kliniky Lékařské fakulty UK a FN Hradec Králové, přednosta prof. MUDr. Jaroslav Malý, CSc.
1; Oddělení klinické hematologie 3. lékařské fakulty UK a FN Královské Vinohrady, Praha, přednosta doc. MUDr. Tomáš Kozák, Ph. D.
2
Published in the journal:
Vnitř Lék 2006; 52(12): 1194-1199
Category:
Review
Summary
B-cell chronic lymphocytic leukemia (B-CLL) represents a heterogeneous disease with variable prognosis. Clinical staging systems (Rai, Binet) fail to accurately predict the prognosis of individual patients, especially in early stages. Modern prognostic markers, mainly the mutational status of the variable regions of immunoglobulin heavy chains (IgVH) and genetic aberrations, allow better risk stratification. Assessment of the expression of intracellular protein tyrosine kinase ZAP-70 represents not only a potential surrogate marker for the technically difficult and routinely unavailable assessment of the IgVH mutational status, but might also be an independent prognostic factor. Study of ZAP-70 function in B-cells has broadened our knowledge on the pathogenesis of B-CLL. Routine ZAP-70 assessment has been hindered so far mainly by the lack of harmonization and standardization of the available methods of detection.
Keywords:
B-cell chronic lymphocytic leukemia - ZAP-70 - flow cytometry - immunohistochemistry - Western blotting - PCR - methylation status
Zdroje
1. Prausová D, Krejsek J, Žák P et al. Význam imunofenotypového vyšetření v diagnostice B-lymfoproliferativních onemocnění. Vnitř Lék 2004; 50: 45-53.
2. Papajík T, Jarošová M, Plachý R et al. Chronická B-lymfocytární leukemie. Část I: Pohled na původ, biologii a genetické změny leukemických buněk. Trans Hemat dnes 2006; 12: 53-61.
3. Hamblin TJ, Davis Z, Gardiner A et al. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999; 94: 1848-1854.
4. Wiestner A, Rosenwald A, Barry TS et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 2003; 101: 4944-4951.
5. Rosenwald A, Alizadeh AA, Widhopf G et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 2001; 194: 1639-1647.
6. Chan AC, Iwashima M, Turck CW et al. ZAP-70: a 70 kd protein-tyrosine kinase that associates with the TCR zeta chain. Cell 1992; 71: 649-662
7. Nolz JC, Tschumper RC, Pittner BT et al. ZAP-70 is expressed by a subset of normal human B-lymphocytes displaying an activated phenotype. Leukemia 2005; 19: 1018-1024.
8. Orchard J, Ibbotson R, Best G et al. ZAP-70 in B-cell malignancies. Leuk Lymphoma 2005; 46: 1689-1698.
9. Rassenti L, Huynh L, Toy TL et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 2004; 351: 893-901.
10. Orchard J, Ibbotson R, Davis Z et al. ZAP-70 expression and prognosis in chronic lymphocytic leukemia. Lancet 2004; 363: 105-111.
11. Crespo M, Bosch F, Villamor N et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003; 348: 1764-1775.
12. Dürig J, Nückel H, Cremer M et al. ZAP-70 expression is a prognostic factor in chronic lymphocytic leukemia. Leukemia 2003; 17: 2426-2434.
13. Orchard J, Best OG, Ibbotson RE et al. ZAP-70 by flow cytometry: Comparison of methodologies, and with IgVH mutational nad ZAP-70 methylation status. (ASH Annual Meeting Abstracts) 2005; 106: 1181.
14. Gibbs G, Bromidge T, Howe D et al. Comparison of flow cytometric methods for the measurement of ZAP-70 expression in a routine diagnostic laboratory. Clin Lab Haem 2005; 27: 258-266.
15. Jorgensen J, Jones D, Luthra R et al. Flow cytometric detection of ZAP-70 in chronic lymphocytis leukemia: addition of a novel second monoclonal antibody improves correlation with IgVH mutation status. Blood (ASH Annual Meeting Abstracts) 2005; 106: 3277.
16. Letestu R, Baran-Marszak F, Lefebvre V et al. Evaluation of ZAP-70 expression using real-time quantitative RT PCR (RQ-PCR) in chronic lymphocytic leukemia (CLL), a reference method for flow cytometry (FCM) harmonization? Blood (ASH Annual Meeting Abstracts) 2005; 106: 1195.
17. Kay S, Herishanu Y, Pick M et al. Quantitative flow cytometry of ZAP-70 levels in chronic lymphocytic leukemia using molecules of equivalent soluble fluorochrome. Cytometry B Clin Cytom 2006; 70: 218-226.
18. Sup SJ, Domiati-Saad R, Kelley TW et al. ZAP-70 expression in B-cell hematologic malignancy is not limited to CLL/SLL. Am J Clin Pathol 2004; 122: 582-587.
19. Admirand JH, Rassidakis GZ, Abruzzo LV et al. Immunohistochemical detection of ZAP-70 in 341 cases of non-Hodgkin and Hodgkin lymphoma. Mod Pathol 2004; 17: 954-961.
20. Carreras J, Villamor N, Colomo L et al. Immunohistochemical analysis of ZAP-70 expression in B-cell lymphoid neoplasms. J Pathol 2005; 205: 507-513.
21. Wang J, Young L, Win W et al. Distribution and ZAP-70 expression of WHO lymphoma categories in Shanxi, China: a review of 447 cases using a tissue microarray technique. Appl Immunohistochem Mol Morphol 2005; 13: 323-332.
22. Vener C, Gianelli U, Cortelezzi A et al. ZAP-70 immunoreactivity is a prognostic marker of disease progression in chronic lymphocytic leukemia. Leuk Lymphoma 2006; 47: 245-251.
23. Kim SZ, Chow KU, Kukoc-Zivojnov N et al. Expression of ZAP-70 protein correlates with disease stage in chronic lymphocytic leukemia and is associated with, but not generally restricted to, non-mutated Ig VH status. Leuk Lymphoma 2004; 45: 2037-2045.
24. Catherwood MA, Matthews C, Niblock R et al. ZAP-70 mRNA quantification in B-cell chronic lymphocytic leukaemia. Eur J Haematol. 2006; 76: 294-298.
25. Laurenti L, Petlickovski A, Rumi C et al. Comparison of ZAP-70/Syk mRNA levels with immunoglobulin heavy-chain gene mutation status and disease progression in chronic lymphocytic leukemia. Haematologica 2005; 90: 1533-1540.
26. Corcoran M, Parker A, Orchard J et al. ZAP-70 methylation status is associated with ZAP-70 expression status in chronic lymphocytic leukemia. Haematologica 2005; 90: 1078-1088.
27. Binet J-L, Caligaris-Capio F, Catovsky D et al. Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia. Blood 2006; 107: 859-861.
28. Scielzo C, Camporeale A, Geuna M. ZAP-70 is expressed by normal and malignant human B-cell subsets of different maturational stage. Leukemia 2006; 20: 689-195.
Štítky
Diabetology Endocrinology Internal medicineČlánok vyšiel v časopise
Internal Medicine
2006 Číslo 12
Najčítanejšie v tomto čísle
- Ultrasound mapping of lower-limb vascular system with regard to occurrence and anatomy of additional front great saphenous vein
- Statins and osteoporosis
- Collagenofibrotic glomerulopathy – rare glomerulonephritis
- Prospective use of EuroSCORE for the short−term risk evaluation of consecutive cardiac surgery candidates: are there any differences in prediction of perioperative risk versus risk of nonsurgical treatments?